Backers included Solas BioVentures and unnamed existing investors.
Led by Jerome Edwards, Co-Founder and CEO, CardioNXT has built a platform of products that enable a better understanding of complex cardiac arrhythmias such as Atrial Fibrillation, and deliver targeted therapy to affected areas within the heart.
The products are also designed to reduce the cost of cardiac catheter ablation procedures.
The company intends to use the funds to advance and obtain regulatory approval for its products in targeted markets (within nine months).
FinSMEs
25/05/2016